Noncoding RNAs in doxorubicin-induced cardiotoxicity and their potential as biomarkers and therapeutic targets.

Acta Pharmacologica Sinica
Hong-Ge FaJian-Xun Wang

Abstract

Anthracyclines, such as doxorubicin (DOX), are well known for their high efficacy in treating multiple cancers, but their clinical usage is limited due to their potential to induce fatal cardiotoxicity. Such detrimental effects significantly impact the overall physical condition or even induce the morbidity and mortality of cancer survivors. Therefore, it is extremely important to understand the mechanisms of DOX-induced cardiotoxicity to develop methods for the early detection of cytotoxicity and therapeutic applications. Studies have shown that many molecular events are involved in DOX-induced cardiotoxicity. However, the precise mechanisms are still not completely understood. Recently, noncoding RNAs (ncRNAs) have been extensively studied in a diverse range of regulatory roles in cellular physiological and pathological processes. With respect to their roles in DOX-induced cardiotoxicity, microRNAs (miRNAs) are the most widely studied, and studies have focused on the regulatory roles of long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs), which have been shown to have significant functions in the cardiovascular system. Recent discoveries on the roles of ncRNAs in DOX-induced cardiotoxicity have prompted extensive inter...Continue Reading

References

Feb 8, 1991·Cell·J M NigroB Vogelstein
Aug 1, 1973·Cancer·E A LefrakJ A Gottlieb
Nov 1, 1980·Biochemical Pharmacology·E GoormaghtighJ M Ruysschaert
Aug 3, 2002·Science·György Hutvágner, Phillip D Zamore
Oct 16, 2002·Biochimica Et Biophysica Acta·Pattie S Green, Christiaan Leeuwenburgh
Apr 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steven E LipshultzSteven D Colan
Nov 1, 2005·Nature·Jan KrützfeldtMarkus Stoffel
Jul 30, 2008·Proceedings of the National Academy of Sciences of the United States of America·Patrick S MitchellMuneesh Tewari
Aug 30, 2008·Proceedings of the National Academy of Sciences of the United States of America·Eva van RooijEric N Olson
Nov 27, 2008·Biochemical and Biophysical Research Communications·Neil Ashley, Joanna Poulton
Feb 4, 2009·Nature Reviews. Genetics·Tim R MercerJohn S Mattick
Mar 17, 2009·American Journal of Physiology. Heart and Circulatory Physiology·Partha MukhopadhyayPál Pacher
Mar 12, 2010·Clinical Science·Yunhui ChengChunxiang Zhang
Sep 18, 2010·Clinical Chemistry·Jessica A WeberKai Wang
Mar 9, 2011·Proceedings of the National Academy of Sciences of the United States of America·Jason D ArroyoMuneesh Tewari
Jun 7, 2011·Circulation. Cardiovascular Genetics·Yasuhide KuwabaraTakeshi Kimura
Feb 4, 2012·Environmental Toxicology and Pharmacology·Jun FuXuetao Wei
Apr 3, 2012·Journal of Molecular and Cellular Cardiology·Yanti OctaviaAn L Moens
May 24, 2012·RNA Biology·Alexander Dalpke, Mark Helm
Aug 4, 2012·PloS One·Caterina Vacchi-SuzziPhilippe Couttet
Oct 20, 2012·Nature Reviews. Drug Discovery·Eva van Rooij, Eric N Olson
Oct 30, 2012·Nature Medicine·Sui ZhangEdward T H Yeh
Mar 1, 2013·Nature·Thomas B HansenJørgen Kjems
Mar 19, 2013·Cell·Pedro J Batista, Howard Y Chang

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.